{"entity":{"id":"nct06950086","kind":"trial","name":"Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of TYK-00540 in HR-positive / HER2-negative breast cancer, run by TYK Medicines, Inc, now recruiting.","summary":"Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06950086 by TYK Medicines, Inc, with 180 participants planned, started 2024-01-02 and due to reach its primary completion in 2026-09. Interventions recorded: TYK-00540.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06950086","url":"https://clinicaltrials.gov/study/NCT06950086"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06950086","phase":"1/2","setting":"A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of the CDK2/4/6 Inhibitor TYK-00540 Tablets in Patients With Advanced Solid Tumors","sponsor":"TYK Medicines, Inc","enrolled":180,"outcomes":[]},"route":"/trials/nct06950086/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}]}}